Feature | March 06, 2014

First Human Implants With Mitral Transcatheter Valve System

Edwards Lifesciences Fortis Mitral Transcatheter Valve System Heart Valve Repair

March 6, 2014 — Edwards Lifesciences Corp. announced the successful completion of the first three human implants of its Fortis mitral transcatheter heart valve. The Heart Team at St. Thomas’ Hospital in London performed them in February and March.

"These first patients had severe mitral valve disease and many risk factors that prevented them from undergoing surgery. After careful evaluation and close consultation with the patients and their families, we determined that this therapy could potentially extend and improve their lives. At this early stage, we are very pleased with the initial recoveries of these patients," said Vinayak Bapat, FRCS CTh, consultant cardiothoracic surgeon, St. Thomas' Hospital in London. 

The hospital's Heart Team ia also led by Martyn Thomas, M.D., FRCP, clinical director of cardiovascular services, and Jane Hancock, M.D., Ph.D., MRCP, consultant cardiologist specializing in imaging. They are experienced in less invasive valve procedures, including transcatheter aortic valve replacement (TAVR).

The Fortis transcatheter mitral valve features Edwards' most advanced, treated bovine pericardial tissue. It features a cloth-covered self-expanding frame designed to minimize paravalvular leak, and an anatomical anchoring system. This series of implants is being performed via a transapical approach to allow direct surgical access to the mitral valve complex.

Edwards expects these cases to be reviewed in the normal course at future medical meetings. The company's transcatheter mitral valve, which utilizes a transapical approach, is not for sale in any country.

For more information: www.edwards.com

Related Content

Edwards Intuity aortic valve, surgical aortic valve replacement, PinnacleHealth, first U.S. implants
News | Heart Valve Technology| August 26, 2016
This week, PinnacleHealth, Harrisburg, Pa., became the first hospital in the country to implant the Edwards Intuity...
Sapien III, Sapien 3, PARTNER III, FDA approval, expanded indication, intermediate risk patients

The Sapien 3 valve has a skirt of fabric at its base that has significantly reduced issues of paravalvular leak, which was an issue with the first generation Sapien device. 

Feature | Heart Valve Technology| August 18, 2016 | Dave Fornell
August 18, 2016 — The U.S.
Sponsored Content | Videos | Heart Valve Technology| August 15, 2016
The Edwards Lifesciences Intuity Elite surgical aortic valve uses a balloon expandable skirt technology taken from th
Edwards Lifesciences, FDA approval, Intuity Elite valve

The Edwards Intuity Elite valve system uses a balloon expandable skirt to anchor the valve rather than traditional sutures.

Technology | Heart Valve Technology| August 15, 2016
August 15, 2016 – Edwards Lifesciences announced the U.S.
mitraclip, mitraclip reimbursement
News | Heart Valve Technology| August 05, 2016
August 5, 2016 — The Centers for Medicare and Medicaid Services (CMS) has reassigned MitraClip transcatheter mitral v
CoreValve Evolut R, intermediate risk patients, european approval, CE mark
Feature | Heart Valve Technology| August 04, 2016
August 4, 2016 — Medtronic announced CE (Conformité Européenne) mark market clearnace for the self-expanding, recaptu
Edwards, Sapien 3 transcatheter heart valve, Canada, approval
News | Heart Valve Technology| July 27, 2016
Edwards Lifesciences Corp. announced that Health Canada has approved the Edwards Sapien 3 transcatheter heart valve for...
mitral valve surgery outcomes, twisting of the heart, echocardiography, NICSMR, JACC Basic to Translational Science
News | Heart Valve Technology| July 20, 2016
A novel study has found a simple pre-operative echocardiographic measurement of the amount of torsion of the heart...
TITAN II Trial, Carillon Mitral Contour System, Cardiac Dimensions, Open Heart journal, functional mitral regurgitation, FMR
News | Annuloplasty Rings| July 20, 2016
New data from the TITAN II trial confirm the safety and efficacy of the Carillon Mitral Contour System in the treatment...
Mitralign, Trialign system, tricuspid regurgitation. SCOUT U.S. study, phase 1 enrollment
News | Heart Valve Technology| July 19, 2016
Mitralign Inc. announced last week it has completed subject enrollment in the SCOUT early feasibility study in the...
Overlay Init